Drug Profile

VLS 1488

Alternative Names: VLS-1488

Latest Information Update: 27 Jan 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Volastra Therapeutics
Class Antineoplastics; Small molecules
Mechanism of Action KIF18A protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I/II Cancer

Most Recent Events

07 Jan 2026 Volastra plans to anticipate an End-of-Phase meeting with the US FDA in the second half of 2026
07 Jan 2026 Volastra plans clinical trial in Ovarian cancer, Lung cancer, and Breast cancers (Combination therapy) in first quarter of 2026
30 May 2025 Efficacy and adverse events data from a phase I/II trial in Cancer presented at the 61^st Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com